FY2026 EPS Estimates for aTyr Pharma Cut by HC Wainwright

aTyr Pharma, Inc. (NASDAQ:ATYR) – Stock analysts at HC Wainwright cut their FY2026 earnings per share estimates for aTyr Pharma in a research report issued to clients and investors on Friday, November 6th. HC Wainwright analyst J. Pantginis now anticipates that the company will earn ($23.57) per share for the year, down from their previous estimate of ($15.60). The consensus estimate for aTyr Pharma’s current full-year earnings is ($17.80) per share. HC Wainwright also issued estimates for aTyr Pharma’s Q4 2026 earnings at ($7.51) EPS, FY2027 earnings at ($10.65) EPS and FY2028 earnings at ($10.00) EPS.

aTyr Pharma (NASDAQ:ATYR) last released its quarterly earnings results on Thursday, November 5th. The company reported ($7.43) EPS for the quarter, missing analysts’ consensus estimates of ($4.00) by ($3.43). The company had revenue of $235.23 million during the quarter, compared to analyst estimates of $2.50 million.

Several other research firms have also recently commented on ATYR. Weiss Ratings cut shares of aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 16th. Wells Fargo & Company upped their target price on aTyr Pharma from $1.00 to $4.00 and gave the company an “equal weight” rating in a report on Friday. Freedom Broker downgraded aTyr Pharma from a “strong-buy” rating to a “hold” rating in a research report on Friday. Royal Bank Of Canada dropped their price target on aTyr Pharma to $6.00 and set a “sector perform” rating on the stock in a report on Friday. Finally, Wall Street Zen raised shares of aTyr Pharma to a “hold” rating in a report on Saturday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, aTyr Pharma currently has a consensus rating of “Hold” and a consensus price target of $5.00.

aTyr Pharma Stock Up 19.4%

ATYR opened at $7.58 on Tuesday. The firm’s fifty day moving average price is $11.40 and its two-hundred day moving average price is $23.48. aTyr Pharma has a 1 year low of $4.07 and a 1 year high of $44.40.

Institutional Trading of aTyr Pharma

An institutional investor recently raised its stake in aTyr Pharma stock. Bank of America Corp DE lifted its holdings in shares of aTyr Pharma, Inc. (NASDAQ:ATYR) by 139.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 303,559 shares of the company’s stock after buying an additional 176,859 shares during the quarter. Bank of America Corp DE owned about 0.31% of aTyr Pharma worth $237,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 61.72% of the company’s stock.

About aTyr Pharma

aTyr Pharma, Inc (NASDAQ:ATYR) is a biotechnology company focused on developing therapies that modulate immune system activity. The company’s research is based on a class of naturally occurring proteins known as extracellular tRNA synthetases, which can influence biological processes involved in inflammation, tissue repair and immune regulation.

aTyr’s lead product candidate is efzofitimod, an engineered protein therapeutic designed to target neuropilin-2 and regulate immune responses in the lungs.